BIOSECURE Act continues to loom over Chinese pharma manufacturers
![](/46/pdcnewsitem/12/50/16/Heading%20image%20(18).png)
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country.
In May 2024, the US House Committee on Oversight and Accountability overwhelmingly voted to approve the act, which passed approval to the full House and Senate, where it received a 40-1 and 11-1 approval vote respectively. While the bill has yet to be signed in by President Joe Biden (delays from disagreement around its inclusion in the 2025 National Defense Authorisation Act have stalled its legislative progression) it has already caused serious implications for Chinese manufacturing companies and their US customers. Revenue for WuXi AppTec, a leading manufacturer in China, fell by 9% - in particular, the company’s US revenue fell by 1% while European revenue rose by 5%. The act also threatens the likes of BGI, MGI, and Complete Genomics.
Described as protecting US national security and financial interests, the act is intended to prevent the access of US funds to Chinese biotechs and manufacturers deemed as ‘companies of concern’. With the US pharmaceutical and biotechnology industry’s reliance on contract manufacturers, the act has prompted concern over its impact on innovation, R&D, and manufacturing for large swathes of medicinal products.
A survey conducted by L.E.K. Consulting demonstrated a sharp decrease in the confidence of many US companies for their Chinese partners – while only 2% have begun the actual process of removing their businesses from China, 26% of companies surveyed are already looking to shift away. However, 11% stated the act currently has no impact on their business decisions, a fact attributed to the uncertainty and fuzzy nature of the bill. In an earnings presentation earlier this week, WuXi stated that the bill “involves uncertainty and multiple steps remain in the legislative process before such proposed legislation is enacted into law.”
Though US pharmaceutical and biotechnology companies are not in total agreement regarding how the act affects their business practices, politicians are a different story. The act received widespread bipartisan support in the Senate and House – the main roadblock is whether the bill will stand on its own or be part of a wider national defense policy.
WuXi addressed their stakeholders, stating they were “actively working together with its advisors to set the record straight and advocate for appropriate changes to the proposed legislation...The Company strongly disagrees with any preemptive and unfair designation of us as a named ‘biotechnology company of concern’ without due process. The Company fully complies with the laws and regulations in the countries and regions in which we operate.” Even so, up to 68% of respondents to L.E.K. Consulting’s survey stated they were in the process of adjusting operations with Chinese partners, including increased legal and compliance requirements, as well as diversifying their supply chain partnerships.
Sources:
[1] With BIOSECURE Act looming, WuXi AppTec shows declining revenue [Accessed July 31, 2024] https://www.fiercepharma.com/manufacturing/bioseecure-act-looming-wuxi-apptec-shows-declining-revenue
[2] BIOSECURE Act hurts US biopharma industry’s confidence in Chinese partners: survey [Accessed July 31, 2024] https://www.fiercepharma.com/pharma/biosecure-act-hurts-life-sciences-companies-confidence-chinese-partners-survey
Related News
-
News Alzheimer’s drug Leqembi rejected by EU drug regulator
The European Medicine’s Agency (EMA), the drug regulator for the EU, rejected Eisai and Biogen’s Alzheimer’s drug product Leqembi, citing the drug’s slowing of cognitive decline did not outweigh the risk of serious brain swellin... -
News Second obesity drug candidate from Roche shows early trial success
Following from its purchase of Carmot Therapeutics, Roche have announced positive early-stage trial success for its second obesity drug candidate acquired from Carmot Therapeutics. -
News Tumour microproteins could provide basis for cancer vaccines
A recent study published in Science Advances has identified a set of microproteins produced exclusively in liver tumours, which may provide a clear target for the development of a cancer vaccine. -
News Reworked once-daily weight-loss pill from Pfizer to progress
American pharmaceutical giant Pfizer have continued with a reworked version of their weight-loss pill danuglipron, progressing with a once-daily version of the pill. -
News CPHI Online Trend Report: what is pharmaceutical packaging really costing the industry?
The latest CPHI Online Trend Report dives into what it really costs to develop, manufacture, and deploy pharmaceutical packaging that balances sustainability concerns, patient safety, and drug efficacy. -
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance